REFERENCES
1. Luna J, Boni J, Cuatrecasas M, Bofill-De Ros X, Núñez-Manchón E, et al. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut 2019;68:1465-76.
3. Sideras K, Braat H, Kwekkeboom J, Van Eijck CH, Peppelenbosch MP, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014;40:513-22.
4. Ischenko I, Petrenko O, Hayman MJ. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget 2015;6:15814.
5. Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep 2013;46:131.
6. Chen J, Chen L, Yu J, Xu Y, Wang X, et al. Meta-analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment-associated toxicities. Mol Med Rep 2019;19:477-89.
7. Zhang Y, Hochster H, Stein S, Lacy J. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol 2015;4:29.
8. Lee HS, Jang CY, Kim SA, Park SB, Jung DE, et al. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Scientific reports 2018;8:1-7.
9. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 response: a surrogate to predict survival in patients with metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2019;42:898-902.
10. Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, et al. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011;11:3665-74.
11. Herrero-Zabaleta ME, Gautier R, Burtin P, Daher N, Bara J. Monoclonal antibody against sialylated Lewis (a) antigen. Bull Cancer 1987;74:387-96.
12. Jelski W, Chrostek L, Szmitkowski M. The activity of class I, II, III, and IV of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in pancreatic cancer. Pancreas 2007;35:142-6.
13. Jelski W, Zalewski B, Szmitkowski M. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer. Dig Dis Sci 2008;53:2276-80.
14. Jelski W, Kutylowska E, Laniewska-Dunaj M, Szmitkowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as candidates for tumor markers in patients with pancreatic cancer. J Gastrointestin Liver Dis 2011;20:255-9.
15. Moniaux N, Andrianifahanana M, Brand RE, Batra SK. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004;91:1633-8.
16. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol 2013;10:607.
18. Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, et al. Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study. J Am Coll Surg 2016;223:52-65.
19. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:4351-8.
20. Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, et al. Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis. Target Oncol 2018;13:461-8.
21. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013;13:340-51.
22. Wu Z, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer. Clin Adv Hematol Oncol 2013;11:50-5.
23. Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas-a retrospective tumor marker prognostic study. Int J Surg 2013;11:1067-72.
24. Paschos KA, Canovas D, Bird NC. The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med 2010;14:165-74.
25. Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, et al. Trefoil factor(s) and CA19. 9: a promising panel for early detection of pancreatic cancer. E BioMedicine 2019;42:375-85.
26. Houghton JL, Abdel-Atti D, Scholz WW, Lewis JS. Preloading with unlabeled CA19. 9 targeted human monoclonal antibody leads to improved PET imaging with 89Zr-5B1. Mol pharm 2017;14:908-15.
27. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 2008;14:4951-60.
28. Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol 2019;11:1758835919853196.
29. Li X, Ma T, Zhang Q, Chen YG, Guo CX, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Lett 2017;406:22-6.
30. Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC cancer 2019;19:252.
31. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016;27:654-60.
32. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6.
33. Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994;9:703-6.
34. Santucci N, Facy O, Ortega-Deballon P, Lequeu JB, Rat P, et al. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology 2018;18:666-70.
35. Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol 2015;21:3157.
36. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, et al. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepato-gastroenterol 2006;53:1-4.
37. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010;17:1794-801.
38. Berger AC, Garcia Jr M, Hoffman JP, Regine WF, Abrams RA, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918.
39. Jawad ZA, Theodorou IG, Jiao LR, Xie F. Highly sensitive plasmonic detection of the pancreatic cancer biomarker CA 19-9. Scientific Rep 2017;7:1-7.
40. Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, et al. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32.
41. Bolton NM, Maerz AH, Brown RE, Bansal M, Bolton JS, et al. Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer. HPB 2019;21:413-8.
42. van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HW, et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB 2018;20:605-11.
43. Xu HX, Li S, Wu CT, Qi ZH, Wang WQ, et al. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology 2018;18:671-7.
44. Choi SH, Park SW, Seong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol 2018;129:340-6.
45. Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, et al. Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study. J Am Coll Surg 2016;223:52-65.
46. Choe JW, Kim HJ, Kim JS, Cha J, Joo MK, et al. Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes. Hepatobiliary Pancreat Dis Int 2018;17:263-8.
47. Zheng W, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? a case report in a patient with pancreatic cancer. Clin Adv Hematol Oncol 2013;11:50-2.
48. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumor Biol 2013;34:3279-92.
49. Lee IK, Kim DH, Gorden DL, Lee YS, Sung NY, et al. Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol 2009;16:861-70.
50. Molina V, Visa L, Conill C, Navarro S, Escudero JM, et al. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumor Biol 2012;33:799-807.
51. Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg 2017;87:987-92.
